Febrile neutropenia. Febrile neutropenia. Febrile neutropenia. Febrile neutropenia 1/30/2019. Infection in patients with cancer
|
|
- Zoe Ross
- 5 years ago
- Views:
Transcription
1 Manit Sae-teaw B.Pharm, BCP, BCOP Glad dip in pharmacotherapy Faculty of pharmaceutical sciences Ubon Ratchathani University Fever Oral temperature measurement of 38.3 C (101.0 F) single 38.0 C (100.4 F) sustained over 1-h period Use of axillary temperature is discouraged Not reflect core body temperature Rectal temperature is avoided Prevent gut organisms Absolute neutrophil count (ANC) Neutropenia ANC < 500 cells/mm3 Expected to decrease to < 500 cells/mm3 during next 48 h Seg : Segmented neutrophil Band : Band form neutrophil Profound neutropenia : ANC < 100 cells/mm 3 Functional neutropenia : qualitative defects of circulating neutrophil Infection in patients with cancer Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia Enrolled 52 patients with leukemia 34 patients were diagnosed ALL 18 patients were diagnosed AML All patients receive chemotherapy treatment 34 patients receive 6-mercaptopurine+prednosilone Ref : Turvey S E et al. Postgrad Med J 2009;85: Ref : Bodey GP, et al. Ann Intern Med. 1966;64:
2 Fever occurs frequently during neutropenia % Solid tumor >80% hematologic malignancy Infectious source can be indentified ~30% 2 Bacteria always identified 85-90% 80% identified pathogen are patients normal flora 3 Common sites of tissue-based infection Respiratory tract, urinary tract, skin, gastrointestinal tract 1 Klastersky J, et al. Clin Infect Dis. 2004;39:S Pizzo PA, et al. N Engl J Med. 1993;328: Schimpff SC, et al. Ann Interm Med 1972;77: Infectious Diseases Society of America (IDSA) Guideline Published in st update nd update 2010 Ref : Freifeld AG, et al. Clin Infect Dis. 2011;52:e Risk assessment of febrile neutropenia To determine The type of empirical antibiotic therapy (IV or Oral) Venue of treatment (Inpatient vs Outpatient) Duration of antibiotic therapy Classification into High risk group and Low risk group MASCC criteria Clinical criteria MASCC : Multinational Association for Supportive Care in Cancer MASCC criteria Charactieristic Weight No or mild symptoms 5 No hypotension (SBP>90 mmhg) 5 No COPD 4 No previous fungal infection 4 No dehydration required parenteral 3 fluids Moderate symptoms 3 Outpatient status 3 Age < 60 years 2 High risk patient defined as MASCC < 21 points Clinical criteria High risk : IV antibiotic in hospital Profound (ANC 100 cells/mm3) and Prolong (anticipated to extend > 7 days) neutropenia Hepatic insufficiency (Aminotransferase >5 ULN) Renal insufficiency (CrCl <30 ml/min) Clinical criteria High risk : IV antibiotic in hospital Presence co-morbid medical problems Hemodynamic instability Mucositis interfere swallowing or severe diarrhea Gastrointestinal symptoms : Abdominal pain Neurologic or mental status change Intravascular catheter infection New pulmonary infiltrate or hypoxemia (or chronic lung disease) 2
3 Clinical criteria High risk : IV antibiotic in hospital Prolong neutropenia is expected as a consequence of HSCT preparation Induction chemotherapy for AML Risk assessment of febrile neutropenia Low risk : Oral antibiotic, Outpatient treatment MASCC score 21 points Neutropenia expected resolved within 7 days and no active medical co-morbidity Prolong neutropenia as a consequence of (MASCC 21 points) Autologous HSCT Consolidation therapy for leukemia Initial assessment Physical examination Signs and symptoms of inflammation are often attenuated Fever is often only sign of infection Assessment should evaluated carefully in most common site of infection Skin, orophalynx, alimentary tract, lung, perinium Initial assessment Laboratory Blood cultures At least 2 sets of blood culture specimens Set : ~20 ml of blood divided into 1 aerobic and 1 anaerobic blood culture In patients weight < 40 kg blood culture should limit to <1% of total blood volume (70 ml/kg) A set collected from each lumen 1 Central 1 peripheral 2 separate venopuncture Optimal testing parameters for blood culture To determine effect of volume of blood, number of cultures, incubation time 37,568 blood cultures tested Number of cultures Pathogen detection 1 set 65.1% 2 sets 80.4% 3 sets 95.7% Ref : Cockerill FR 3rd, et al. Clin Infect Dis. 2004;38: Initial assessment Laboratory Specific site cultures Site Indication Detection Stool Diarrhea C.Difficile toxin Urine UTI symptoms, Urine culture Catheter, Abnormal UA CSF Meningitis Spinal fluid culture Skin Skin lesion Skin biopsy or aspiration Respiratory Productive cough Sputum culture Nasal wash or BAL BAL : Bronchoalveolar lavage 3
4 General consideration Observational study observe > 2,000 febrile neutropenia pts reveals Only 23% associated with bacteremia Frequencies of bacteremia Gram-positive : 57% Gram-negative : 34% Polymicrobial : 9% Gram negative associated with greater mortality (esp. P. aeruginosa) High risk Require hospitalization for IV empirical antibiotic Monotherapy with anti-pseudomonal β-lactam agent Cefepime Carbapenem Piperacillin-tazobactam Other antimicrobials may be added to manage complication Hypotension, pneumonia Ref : Klastersky J, et al. Int J Antimicrob Agents. 2007;30:S51-9. Vancomycin Indication for addition antibiotic against Gram positive organism Hemodynamic instability Pneumonia documented radiographically Positive blood culture for Gram positive infection Serious catheter related infection Skin and soft tissue infection Colonization with MRSA, PRSP Severe mucositis, if previous fluoroquinolone prophylaxis and ceftazidime use for empirical therapy Penicillin allergy Most penicillin allergic patients can use cephalosporins Immediate type hypersensitivity reaction (hives and brochospasm) Avoid β-lactam antibiotic Ciprofloxacin plus clindamycin Aztreonam plus vancomycin Low risk Medication therapy include Ciprofloxacin plus amoxicillin-clavulanate Moxifloxacin Levofloxacin or ciprofloxacin monotherapy Ciprofloxacin plus clindamycin Previous quinolone prophylaxis should not receive oral empirical quinolone Modified antimicrobial Monitoring efficacy and safety should be evaluated Median time to defervescence Solid tumor : 2 days Hematologic malignancy (include HSCT) : 5 days Specific antimicrobial addition or change to initial regimen guide by clinical and culture result 4
5 Modified antimicrobial Should be guided by clinical and microbiologic data Unexplained persistent fever Clinical stable : Not require antibiotic change Clinical unstable : Broadened antimicrobial Vancomycin may be stopped after 2 days (If no gram positive infection) Low risk patients require hospitalized if fever persist >48 hours Empirical antifungal should be considered after 4-7 days of antibacterial treatment IV-to-Oral switch may be made if Clinically stable Gastrointestinal absorption is adequate Duration of antimicrobial treatment Clinical and microbiology documented Treatment until neutropenia resolved Clinically necessary Unexplained fever (No microbiological documented) Treatment until neutropenia resolved Alternatively if treatment course has been completed Patients who remain neutropenia may resume oral quinolone until marrow recovery Empirical antifungal High risk patient are risk for invasive fungal infection Manifested by persistent or recurrent fever in neutropenic patients Yeast infection Candida species (the most common) Can occur 4-7 days of neutropenia Invasive mold infection : Aspergillosis (the most common) Related to profound (ANC<100 cells/mm3), prolong (>10-15 days) neutropenia Empirical/Preemtive antifungal No antifungal prophylaxis patients Amphotericin B (conventional) Fluconazole Other antifungal Previous antifungal prophylaxis Fluconazole prophylaxis Amphotericin B (standard empirical) Alternative itraconazole, voriconazole, caspofungin Mold-active prophylaxis Switch to IV mold active agent in difference class s Recommended guideline American society of clinical oncology (ASCO) European organisation for research and treatment of cancer (EORTC) National comprehensive cancer network 3 Indication Primary prophylaxis Secondary prophylaxis Treatment during febrile neutropenia 1 Smiths TJ, et al. J Clin Oncol. 2015;33: Aapro MS, et al. Eur J Cancer. 2011;47: Available at : 5
6 Primary prophylaxis Chemotherapy FN risk > 20% American Society of Clinical Oncology (ASCO) guideline updates 2015 Chemotherapy with febrile neutropenia risk 20% Intensive chemotherapy regimen Dose-dense (increased frequency) Dose-intense (increased dose) High risk patient Type Breast Esophargeal H&N NHL Lung cancer Ovarian Regimen AC>D, TAC, TC, Doxetaxel+Cyclophosphamide TCF Paclitaxel+ifosfamide ESHAP, R-ICE Docetaxel+Carboplatin, Topotecan Topotecen, Docetaxel Primary prophylaxis High risk patient Age 65 years Advanced disease Previous chemotherapy and radiation therapy Preexisting neutropenia or bone marrow involvement with tumor Infection Open wound or recent surgery Poor performance status or poor nutritional status Poor renal function Liver dysfunction (most notable elevated bil) Cardiovascular disease Multiple comorbid conditions HIV infection Secondary prophylaxis Recommended for patients who experienced a neutropenic complication from a prior cycle of chemotherapy Especially in reduced dose may compromise therapeutic outcome Treatment Restrict use in high risk FN patients Sepsis syndrome Age > 65 years Profound neutropenia (ANC < 100 cells/mm 3 ) Neutropenia expected to last > 10 days Pneumonia Invasive fungal infection Other clinically documented infections Hospitalization at time of fever Prior episode of febrile neutropenia Acute leukemia and Myelodysplastic syndromes Acute myeloid leukemia (AML) Not recommended in induction phase prophylaxis Recommended in consolidation phase prophylaxis Myelodysplastic syndromes (MDS) Recommended treatment intermittent in severe neutropenia and recurrent infection Acute lymphocytic leukemia (ALL) Recommended in induction phase prophylaxis Ref : Smiths TJ, et al. J Clin Oncol. 2006;24:
7 Compare colonystimulating factors s Filgrastim Lenograstim Sargamostim Pegfilgrastim Source E.Coli - Yeast Yeast Dose 5 mcg/kg/d 5 mcg/kg/d 250 mcg/m2/d 6 mcg single dose** Route SC, IV SC,IV SC,IV SC Half life 3.5 hr 3 hr 2 hr hr Eliminate Renal Renal - Neutrophil Adverse effect Bone pain, Bruising, diarrhea*, edema*, fatigue*, fever*, rash, injection site reaction Bone pain, injection site reaction, urticaria * Less frequent with filgrastim compare with sargamostim ** Do not used in infants and children and BW < 45 kg Ref : Molineux G. Current Pharmaceutical Design. 2004;10: s s Ref : Crawford J. Drugs. 2002;62: Ref : Holmes FA, et al. J Clin Oncol. 2002;20: Compare colonystimulating factors Filgrastim Lenograstim Sargamostim Pegfilgrastim Source E.Coli - Yeast Yeast Dose 5 mcg/kg/d 5 mcg/kg/d 250 mcg/m2/d 6 mg single dose** Route SC, IV SC,IV SC,IV SC Half life 3.5 hr 3 hr 2 hr hr Eliminate Renal Renal - Neutrophil Adverse effect Bone pain, Bruising, diarrhea*, edema*, fatigue*, fever*, rash, injection site reaction * Less frequent with filgrastim compare with sargamostim ** Do not used in infants and children and BW < 45 kg Bone pain, injection site reaction, urticaria Colonystimulating factor regimen Colonystimulating factor Filgrastim : 5 mcg/kg/day Lenograstim : 5 mcg/kg/day Pegfilgrastim : 6 mg Duration Should started 24 to 72 hours after chemotherapy Continued up to 14 days (prophylaxis) or until reaching ANC 3,000 cells/mm 3 for 2 consecutive days (treatment) Pegfilgrastim : single dose (only prophylaxis) 7
8 Von Minckwitz G, et al. 1 Compare G-CSF (5-10 days) vs Pegfilgrastim Out come : febrile neutropenia incidence G-CSF 18%, Pegfilgrastim 7% (P<0.001) Almenar D, et al 2 and Morrison VA, et al. 3 Study G-CSF used in real world practice Median number of daily G-CSF is 6-7 days More patients have febrile neutropenia compare with pegfilgrastim (41%) Environmental precautions Hand hygiene Isolation and barrier precustions HSCT should be placed in private room With > 12 air exchanged/hr HEPA filtration Plants and dried fresh flowers should not allowed Hospital work exclusion policies application 1 von Minckwitz G, et al. Ann Oncol. 2008;19: Almenar D, et al.eur J Cancer Care (Engl) 2009;18: Morrison VA, et al. J Manag Care Pharm. 2007;13:
Role of Pharmacist in Supportive care cancer
Role of Pharmacist in Supportive care cancer Manit Sae-teaw B.Pharm, BCOP, BCP Grad. Dip. In Pharmacotherapy Faculty of Pharmaceutical Science Ubon Ratchathani University 1 Outline Cancer facts Supportive
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationReady to answer the questions?
파워포인트문서의제목 Reference 1. IDSA GUIDELINES. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America.
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationGuidelines in the Management of Febrile Neutropenia for Clinical Practice
REFERENCES 1. Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States: has the burden shifted over time? Cancer. 2010;116(14):3477-3484.
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationComparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia
Comparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia I. Malik ( National Cancer lnsititute, Karachi ) Shaharyar (, Department of Radiotherapy
More informationUPDATE ON FEBRILE NEUTROPENIA
UPDATE ON FEBRILE NEUTROPENIA Clinical approach and management Dr.Shafiq A. Alimad Head of medical department at university of science and technology hospital YICID 15-December-2014 INTRODUCTION Cancer
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationIDSA GUIDELINES EXECUTIVE SUMMARY
IDSA GUIDELINES Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America Alison G. Freifeld, 1 Eric
More informationFEBRILE NEUTROPENIA CURRENT GUIDELINES FOR CHILDREN Alia Zaidi, MD. St. Jude International Outreach Program
SIOP PODC Supportive Care Education (ICON 2016) Presentation Date: 23 rd January 2016 Recording Link at www.cure4kids.org: https://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p25oti35nt7
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationNeutropenic Fever. CID 2011; 52 (4):e56-e93
Neutropenic Fever www.idsociety.org CID 2011; 52 (4):e56-e93 Definitions Fever: Single oral temperature of 101 F (38.3 C) Temperature 100.4 F (38.0 C) over 1 hour Neutropenia: ANC < 500 cells/mm 3 Expected
More informationCANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS
CANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand Learning Objectives Summarize national guidelines
More information8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications
Dean Van Loo Pharm.D. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Steroids Biologics Antineoplastic Most data from cancer chemotherapy Bone marrow suppression Fever is the
More informationPerformance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
DOI 10.1007/s00520-007-0347-3 ORIGINAL ARTICLE Performance of a modified MASCC index score for identifying low- febrile neutropenic cancer patients Luciano de Souza Viana & José Carlos Serufo & Manoel
More informationProphylaxis of febrile neutropenia :experiences with adjuvant TAC
Prophylaxis of febrile neutropenia :experiences with adjuvant TAC 30 th Apr, 2016 Jihyoun Lee Breast center, Department of Surgery Soonchunhyang University Hospital Chemotherapy and the risk of febrile
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationMICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS
When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationUICC EML Review 2014
UICC EML Review 2014 Granulocyte Stimulating Agents (G- CSF) Supplemental Document Many antineoplastic agents are cytotoxic to the bone marrow and prevent the development of granulocytes necessary to fight
More informationSupplemental Online Case Discussion: Febrile Neutropenia
Supplemental Online Case Discussion: Febrile Neutropenia Alison C. Young, Fiona J. Collinson St James s Institute of Oncology, St James s University Hospital, Leeds, West Yorkshire, United Kingdom Case
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationSUPPLEMENT ARTICLE DEFINITIONS
SUPPLEMENT ARTICLE The Infectious Diseases Society of America 2002 Guidelines for the Use of Antimicrobial Agents in Patients with Cancer and Neutropenia: Salient Features and Comments Kenneth V. I. Rolston
More informationGuideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation
Guideline for the Management of Fever Neutropenia in Children with Cancer /or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs.
More information2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationChoc septique. Frédéric Pène
Choc septique Frédéric Pène Réanimation Médicale, Hôpital Cochin, AP-HP Université Paris Descartes Institut Cochin, Inserm U1016, CNRS UMR-8104, Département 3i No conflict of interest A 54 y.o. male patient
More informationMANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSP There are no translations available. MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
More informationClinical characteristics and therapeutic outcome of patients with febrile neutropenia: Our clinical experience
International Journal of Clinical Medicine Research 2014; 1(1): 26-30 Published online April 30, 2014 (http://www.aascit.org/journal/ijcmr) Clinical characteristics and therapeutic outcome of patients
More informationINTRODUCTION. O riginal A rticle. Singapore Med J 2012; 53(11) : 720
Singapore Med J 2012; 53(11) : 720 Risk factors for adverse outcomes and multidrugresistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationHospital-acquired Pneumonia
Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationNeutropenic Sepsis Acute General Management and Support. Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology
Neutropenic Sepsis Acute General Management and Support Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology Who Am I? I am A Medical Oncologist (MCCN) Site specialist
More informationPAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY
PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY Purpose: This document is intended as a guide to the investigation and management of children presenting in Salisbury District Hospital with suspected neutropenic
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationCorporate Medical Policy
White Blood Cell Growth Factors Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: white_blood_cell_growth_factors 9/2016 4/2017 4/2018 6/2017 Description of
More informationInfections in Oncology
Infections in Oncology Early Empiric Antibiotic Therapy for Febrile Neutropenia Patients at Low Risk Kenneth V. I. Rolston, MD, Edward B. Rubenstein, MD, of The University of Texas M.D. Anderson Cancer
More informationReference No: SG 23/13
Title: Author(s) Ownership: Approval by: Guidelines for the use of granulocyte colony stimulating factor (GSCF) in adult oncology & malignant haematology patients Paula Scullin, Consultant Medical Oncologist,
More informationCircle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]
04/25/2016 Prior Authorization AETA BETTER HEALTH OF LA MEDICAID Colony Stimulating Factors (LA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationGUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA)
GUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA) Document Reference: N/A Version: V1.1 Dr Andrew Sykes Document Document June So Owner: Chair Drugs & Author: Director of Pharmacy Therapeutics
More informationMonitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio )
Monitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio ) Heinz Ludwig Wilhelminen Cancer Research Institute c/o I
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationFebrile Neutropenia in Intensive Care Unit
ICU Rounds Febrile Neutropenia in Intensive Care Unit Nattamol Hosiriluck MD, Saba Radhi MD Abstract Febrile neutropenia is a serious complication of cancer treatment and causes significant morbidity and
More informationLack of benefit of Granulocyte Macrophage or Granulocyte Colony Stimulating Factor in Patients with Febrile Neutropenia
Lack of benefit of Granulocyte Macrophage or Granulocyte Colony Stimulating Factor in Patients with Febrile Neutropenia T. Siddiqui,I. A. Burney,A. Salam ( Departments of Medicine, The Aga Khan University
More informationPekka Riikonen. Introduction
Recombinant Human Granulocyte-Macrophage Colony-S timulating Factor in Combination with Antibiotics in the Treatment of Febrile Neutropenia in Children Pekka Riikonen Kuopio University Hospital, Division
More informationCircle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.
10/01/2016 Prior Authorization Aetna Better Health of West Virginia COLO STIMULATIG FACTORS (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationLa neutropenia febbrile
XII Corso Avanzato di Terapia Antibiotica Pisa, 15-16 novembre 2017 La neutropenia febbrile Alessandra Micozzi Dipartimento di Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Fever developing
More informationNeutropenic Fever 1 InpatientPediatric Treatment
Neutropenic Fever InpatientPediatric Treatment (Hematologic Cancers and Stem Cell Patients) te: This algorithm should not be used for patients receiving CAR cell therapy. Page of 8 Patient presents with
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationAilyn T. Isais-Agdeppa, MD*, Lulu Bravo, MD*
A FIVE-YEAR RETROSPECTIVE STUDY ON THE COMMON MICROBIAL ISOLATES AND SENSITIVITY PATTERN ON BLOOD CULTURE OF PEDIATRIC CANCER PATIENTS ADMITTED AT THE PHILIPPINE GENERAL HOSPITAL FOR FEBRILE NEUTROPENIA
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationFebrile Neutropenia. Laura J. Zitella, MS, RN, ACNP-BC, AOCN Nurse Practitioner Clinical Associate Professor University of California San Francisco
Febrile Neutropenia Laura J. Zitella, MS, RN, ACNP-BC, AOCN Nurse Practitioner Clinical Associate Professor University of California San Francisco What Are The Facts About Febrile Neutropenia (FN)? Fever
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationClinical profile of high-risk febrile neutropenia in a tertiary care hospital
Clinical profile of high-risk febrile neutropenia in a tertiary care hospital Mohan V Bhojaraja 1, Sushma T Kanakalakshmi 2, Mukhyaprana M Prabhu 1, Joseph Thomas 3 1. Department of Medicine, Kasturba
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationAdvanced Pediatric Emergency Medicine Assembly
(+)Joan Shook, MD, FACEP Professor of Pediatrics, Baylor College of Medicine; Chief Safety Officer and Chief Clinical Information Officer, Texas Children's Hospital Advanced Pediatric Emergency Medicine
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationNeutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt
More informationANTIEMETICS and FEBRILE NEUTROPENIA. Matti S. Aapro Genolier Switzerland
ANTIEMETICS and FEBRILE NEUTROPENIA Matti S. Aapro Genolier Switzerland 2010 Multinational Association of Supportive Care in Cancer TM All rights reserved worldwide. Disclosures Collaborations in this
More informationEvaluation of Febrile Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation
ORIGINAL REPORT Evaluation of Febrile Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation Shahideh Amini 1, Molouk Hadjibabaie 2, Zahra Jahangard-Rafsanjani 1, Asieh Ashuri 3, Hassan
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Febrile Neutropenia. These podcasts are designed to give medical students an overview of key topics in pediatrics. The
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationPreventing Neutropenic Complications
Preventing Neutropenic Complications Michael Rader, MD Clinical Assistant Professor of Medicine, Columbia University College of Physicians and Surgeons Director, Union State Bank Cancer Center at Nyack
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationPiperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases
ORIGINAL PAPER Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases O. R. Sipahi, 1 B. Arda, 1 A. Nazli-Zeka, 1 H. Pullukcu, 1 M. Tasbakan, 1 T. Yamazhan, 1 S.
More informationAspiration pneumonia in older people
Aspiration pneumonia in older people Ayman Morish, M.D. Internal medicine, Critical care Medicine and Geriatrics Fellow. Contents Epidemiology Causes of aspiration pneumonia Issues of older age Management
More informationPublished Ahead of Print on January 14, 2013 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on January 14, 2013 as 10.1200/JCO.2012.45.8661 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2012.45.8661 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationFor peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation
Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationInteractive Cases. Victor Tseng, MD
Interactive Cases Victor Tseng, MD WHO HAS A NEUTROPENIC FEVER? 61 M ANC 800 + T 38.9 being treated for stage IIIA CRC 22 F ANC 120 + T 37.0 getting consolidation for ALL 53 F ANC 580 (710 yesterday)
More informationChanges in Etiologic Microorganisms in Thai Patients with Chemotherapy-Induced Neutropenia and Fever
Original Article Changes in Etiologic Microorganisms in Thai Patients with Chemotherapy-Induced Neutropenia and Fever Chonticha Auesomwang MD 1, Bundarika Suwannawiboon MD 2, Methee Chayakulkeeree MD,
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationProspective audit and feedback of piperacillin-tazobactam use in a 1115 bed acute care hospital
Prospective audit and feedback of piperacillin-tazobactam use in a 1115 bed acute care hospital Final Results Nathan Beahm, BSP, PharmD(student) September 10, 2016 Objectives Review background information
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationPILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS
PILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS RATIONALE: It is increasingly being recognised that not all neutropenic patients have the same risk of complications during episodes
More informationManagement of common chemotherapy related side effects. Dr Lee-Ann Jones
Management of common chemotherapy related side effects Dr Lee-Ann Jones Deciphering oncology terms treatment intent Chemotherapy terms / intents Adjuvant chemotherapy - Chemotherapy given to destroy residual/
More informationNeupogen (Filgrastim)/Neulasta (Pegfilgrastim)
Policy Number Reimbursement Policy NEU12182013RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 12/18/2013 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationInfections in acute leukemia in Indian Children
Journal of College of Medical Sciences-Nepal, 2013, Vol-9, No-1, 40-47 Infections in acute leukemia in Indian Children Original Article B Roy, 1 A Biswas, 2 A Chaterjee, 3 A Pan 4, K Basu 5 1 Associate
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for
More informationSpecial Considerations for the Oncology Patient in the ICU
FSHP 2017 ANNUAL MEETING Disclosure Special Considerations for the Oncology Patient in the ICU I do not have (nor does any immediate family member have) a vested interest in or affiliation with any corporate
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationGuidelines for the use of G-CSF in the Department of Oncology
Guidelines for the use of G-CSF in the Department of Oncology Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationDr. Arghya Samanta PG-3 Department of Pediatrics
Dr. Arghya Samanta PG-3 Department of Pediatrics A 3 year old male K/C/O B-cell Acute lymphoblastic leukemia Undergoing induction phase of chemotherapy On day 23 of induction Presented with - high grade
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationUrinary tract infection. Mohamed Ahmed Fouad Lecturer of pediatrics Jazan faculty of medicine
Urinary tract infection Mohamed Ahmed Fouad Lecturer of pediatrics Jazan faculty of medicine Objectives To differentiate between types of urinary tract infections To recognize the epidemiology of UTI in
More information